Europe
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Amarin announced the forthcoming retirement of President and CEO John Thero, and the elevation of current head of commercial for Europe and senior vice president Karim Mikhail to the top role.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
The new factory will include cutting-edge technology, allowing production of three to four vaccines simultaneously, a massive improvement on the current limitation of one vaccine in an industrial site.
AstraZeneca’s diabetes drug Farxiga (dapagliflozin) failed to reach endpoints in a Phase III study as a potential treatment for hospitalized COVID-19 patients serious risk of developing complications.
Tidal Therapeutics, which does not even have a website, came out of LabCentral in Cambridge. It focuses on developing nanoparticles able to deliver messenger RNA (mRNA) that can reprogram immune cells.
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
The technology also has intriguing potential in DNA forensics, even without the presence of other physical samples.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
PRESS RELEASES